TIMELINE

October 26, 2017

Actuate Therapeutics receives rare pediatric disease designation for 9-ING-41 for treatment of neuroblastoma.
(press release)

August 18, 2017

FDA grants an additional Orphan Drug Designation for 9-ING-41 for the treatment of neuroblastoma.

June 17, 2017

Actuate closes Series A Financing totaling $3.8M

April 3, 2017

Dr. Matsangou presents research on GSK-3B and its role in head and neck carcinoma at the AACR meeting in Washington, DC.
(poster)

March 31, 2017

Actuate technologies featured in the Molecular Pathways special feature section in the journal Clinical Cancer Research.

(press release)    (journal article)

March 1, 2017

Dr. Francis J. Giles joins Actuate as Chief Medical Officer. (press release)

March 29, 2016

FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma.

December 18, 2015

Actuate receives a favorable FDA Written Response to our Pre-IND Plan for the development of 9-ING-41. The FDA laid out a very clear path on tasks necessary to complete in order to submit an IND, which sets the company up well for advancing 9-ING-41 into the clinic, and ultimately, to effectively treating patients.

December 11, 2015

Actuate completes initial financing.

November 19, 2015

Andrey Ugolkov presents his work the use of 9-ING-41 in treatment-sensitive and treatment-resistant glioblastoma at the Society of Neuro Oncology meeting. (see attachment)

October 29, 2015

Actuate Forms Scientific Advisory Board

April 20, 2015

Drs. Dubrovsky and Ugolkov present research on GSK-3B and its role in neuroblastoma and glioblastoma at the AACR meeting in Philadelphia.
(Poster 1)
(Poster 2)

April 16, 2015

License agreements are executed with both UIC and Northwestern for the technology and know-how that serves as the foundational intellectual property for Actuate Therapeutics.

Jan 16, 2015

Company is incorporated as Apotheca Therapeutics, Inc, a Delaware C Corp, with Headquarters in Fort Worth, Texas.